Bayer HealthCare LLC Increases Stake in Senti Biosciences to 17.82%

Bayer HealthCare LLC, along with Bayer US Holding LLC and managers Sebastian Guth and Priyal Patel, filed an amendment to their Schedule 13D on April 16, 2026, regarding their investment in Senti Biosciences, Inc. (SNTI). The reporting persons collectively beneficially own 6,142,848 shares of Common Stock, representing a 17.82% ownership stake. This position includes 3,333,000 shares of Common Stock issuable upon the exercise of a warrant held by Bayer Healthcare LLC that is currently exercisable or will become exercisable within 60 days. The filing reflects an increase in holdings from a previously reported zero balance to the current 17.82% threshold. The calculation of this ownership percentage is based on 31,144,497 shares of Common Stock outstanding as of March 19, 2026. The reporting persons share voting and dispositive power over the reported shares. The filing also includes a new Power of Attorney for Priyal Patel as an exhibit.